Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NKTR NASDAQ:URGN NASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNKTRNektar Therapeutics$66.61-2.9%$77.98$7.99▼$109.00$2.25B1.24907,717 shs548,000 shsURGNUrogen Pharma$28.89-3.3%$22.71$3.61▼$32.37$1.41B1.58920,799 shs364,372 shsVERVVerve Therapeutics$11.13$11.13$3.89▼$11.41$992.13M2.234.91 million shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNKTRNektar Therapeutics0.00%-5.68%-27.01%-9.66%+602.08%URGNUrogen Pharma0.00%+0.38%+18.84%+37.11%+592.81%VERVVerve Therapeutics0.00%0.00%0.00%0.00%+163.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNKTRNektar Therapeutics$66.61-2.9%$77.98$7.99▼$109.00$2.25B1.24907,717 shs548,000 shsURGNUrogen Pharma$28.89-3.3%$22.71$3.61▼$32.37$1.41B1.58920,799 shs364,372 shsVERVVerve Therapeutics$11.13$11.13$3.89▼$11.41$992.13M2.234.91 million shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNKTRNektar Therapeutics0.00%-5.68%-27.01%-9.66%+602.08%URGNUrogen Pharma0.00%+0.38%+18.84%+37.11%+592.81%VERVVerve Therapeutics0.00%0.00%0.00%0.00%+163.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNKTRNektar Therapeutics 2.73Moderate Buy$149.63124.63% UpsideURGNUrogen Pharma 2.80Moderate Buy$36.6726.92% UpsideVERVVerve Therapeutics 2.00Hold$12.6013.21% UpsideCurrent Analyst Ratings BreakdownLatest VERV, NKTR, and URGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026URGNUrogen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.005/11/2026URGNUrogen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.005/11/2026NKTRNektar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$95.00 ➝ $80.005/11/2026URGNUrogen Pharma LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$43.005/8/2026NKTRNektar Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$105.00 ➝ $192.005/7/2026URGNUrogen Pharma OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $40.004/24/2026URGNUrogen Pharma Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/22/2026NKTRNektar Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/21/2026NKTRNektar Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$123.00 ➝ $151.004/21/2026NKTRNektar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$70.00 ➝ $95.004/20/2026URGNUrogen Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNKTRNektar Therapeutics$55.23M40.75N/AN/A$17.06 per share3.90URGNUrogen Pharma$109.79M12.82N/AN/A($2.55) per share-11.33VERVVerve Therapeutics$32.33M30.69N/AN/A$5.83 per share1.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNKTRNektar Therapeutics-$164.08M-$8.42N/AN/AN/A-284.18%-85.40%-39.99%8/6/2026 (Estimated)URGNUrogen Pharma-$153.49M-$2.75N/A20.64N/A-94.83%N/A-62.85%8/6/2026 (Estimated)VERVVerve Therapeutics-$198.71M-$2.11N/AN/AN/A-303.64%-35.81%-27.57%N/ALatest VERV, NKTR, and URGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026NKTRNektar Therapeutics-$1.5824-$1.82-$0.2377-$1.82$10.69 million$10.86 million5/7/2026Q1 2026URGNUrogen Pharma-$0.4824-$0.47+$0.0124-$0.47$44.83 million$50.96 million3/12/2026Q4 2025NKTRNektar Therapeutics-$2.69-$1.78+$0.91-$1.78$10.44 million$21.81 million3/2/2026Q4 2025URGNUrogen Pharma-$0.66-$0.54+$0.12-$0.54$39.92 million$37.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNKTRNektar TherapeuticsN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNKTRNektar TherapeuticsN/A10.2110.21URGNUrogen PharmaN/A4.694.28VERVVerve TherapeuticsN/A9.849.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNKTRNektar Therapeutics75.88%URGNUrogen Pharma91.29%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipNKTRNektar Therapeutics2.50%URGNUrogen Pharma4.70%VERVVerve Therapeutics19.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNKTRNektar Therapeutics22033.79 million32.94 millionOptionableURGNUrogen Pharma20048.72 million46.43 millionOptionableVERVVerve Therapeutics11089.14 million71.94 millionOptionableVERV, NKTR, and URGN HeadlinesRecent News About These CompaniesThree Biotechs That Are Top Takeover TargetsMay 18, 2026 | 247wallst.comEuropean Biotechs Developing Next-Generation of Cardiometabolic and Precision Cardiology TherapeuticsApril 14, 2026 | pharmtech.comPStudies test whether gene-editing can fix high cholesterolFebruary 17, 2026 | tribtoday.comTStudies test whether gene-editing can fix high cholesterol. For now, take your medicineFebruary 13, 2026 | courant.comCBeyond Obesity: Lilly Inks Up to $11.25B in Cancer, Immune System DealsFebruary 10, 2026 | genengnews.comGLilly Doubles Down on Eye Diseases, Adding to BD SpreeNovember 10, 2025 | biospace.comBCRISPR gene-editing works to reduce high cholesterol in a new studyNovember 9, 2025 | wkms.orgWGene Therapy Shows Promise for Cutting LDL in Half in Tough-to-Treat DyslipidemiaNovember 9, 2025 | msn.comHow a ‘one and done’ gene-editing treatment could lower cholesterolNovember 8, 2025 | msn.comA Gene Editing Therapy Cut Cholesterol Levels by HalfNovember 8, 2025 | wired.comWHyperlipidemia Drugs Market Report 2025: $24.74 Industry Led by Pfizer, Merck & AbbVie, With Asia-Pacific Poised for Strong Growth Amid Trade-Driven Supply Chain Shifts ...November 4, 2025 | finance.yahoo.comShifting PCSK9 inhibition ‘upstream’ for high-risk primary preventionNovember 4, 2025 | healio.comHIntellia pauses two late-stage CRISPR gene-editing trials after emergence of safety concernOctober 27, 2025 | statnews.comSEli Lilly bets on eye care with buyout of gene therapy developer AdverumOctober 24, 2025 | msn.comPCSK9’s second act: From antibodies to gene editingOctober 22, 2025 | labiotech.euLProgress and Pressure: Taking Stock of the CRISPR LandscapeOctober 16, 2025 | medscape.comMOdyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of DirectorsOctober 9, 2025 | finance.yahoo.comPCSK9 Inhibitors Market Analysis 2034 – Competitive Landscape, Clinical Trials, Market Share, Medication, Patient Population, Companies by DelveInsightOctober 7, 2025 | theglobeandmail.comCRISPR Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsightOctober 2, 2025 | finance.yahoo.comAIRNA Appoints Allison Dorval as Chief Financial Officer and Niru Subramanian as Chief Operating OfficerOctober 1, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVERV, NKTR, and URGN Company DescriptionsNektar Therapeutics NASDAQ:NKTR$66.61 -1.97 (-2.87%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$66.51 -0.10 (-0.15%) As of 05/22/2026 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Urogen Pharma NASDAQ:URGN$28.89 -0.99 (-3.31%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$28.90 +0.01 (+0.03%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Verve Therapeutics NASDAQ:VERVVerve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
